{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:01:19Z","timestamp":1780124479715,"version":"3.54.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG8N0661"],"award-info":[{"award-number":["CMRPG8N0661"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG3M1501"],"award-info":[{"award-number":["CMRPG3M1501"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11604-026-01947-1","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:52:48Z","timestamp":1770277968000},"page":"1085-1094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intensity-modulated proton therapy for patients with unresectable giant (\u2265\u200910\u00a0cm) hepatocellular carcinoma: a retrospective analysis from two high-volume centers"],"prefix":"10.1007","volume":"44","author":[{"given":"Jen-Yu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-Yen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-You","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Hwei","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0477-448X","authenticated-orcid":false,"given":"Bing-Shen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"7","key":"1947_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/hpb.12416","volume":"17","author":"C Lim","year":"2015","unstructured":"Lim C, Compagnon P, Sebagh M, Salloum C, Calderaro J, Luciani A, et al. Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery. HPB. 2015;17(7):611\u201323.","journal-title":"HPB"},{"issue":"5","key":"1947_CR2","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jamcollsurg.2003.07.013","volume":"197","author":"KT Mok","year":"2003","unstructured":"Mok KT, Wang BW, Lo GH, Liang HL, Liu SI, Chou NH, et al. Multimodality management of hepatocellular carcinoma larger than 10 cm. J Am Coll Surg. 2003;197(5):730\u20138.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"1947_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1365-2036.2006.02704.x","volume":"23","author":"YH Huang","year":"2006","unstructured":"Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther. 2006;23(1):129\u201335.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1947_CR4","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/liv.12436","volume":"34","author":"KH Kim","year":"2014","unstructured":"Kim KH, Kim MS, Chang JS, Han KH, Kim DY, Seong J. Therapeutic benefit of radiotherapy in huge (>\/=10 cm) unresectable hepatocellular carcinoma. Liver Int. 2014;34(5):784\u201394.","journal-title":"Liver Int"},{"key":"1947_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-120","volume":"9","author":"JY Que","year":"2014","unstructured":"Que JY, Lin LC, Lin KL, Lin CH, Lin YW, Yang CC. The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities. Radiat Oncol. 2014;9:120.","journal-title":"Radiat Oncol"},{"issue":"5","key":"1947_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3892\/mco.2014.304","volume":"2","author":"NB Zhong","year":"2014","unstructured":"Zhong NB, Lv GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (>\/=10 cm) hepatocellular carcinomas: a clinical study. Mol Clin Oncol. 2014;2(5):839\u201344.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"1947_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0504-3","volume":"32","author":"T Xue","year":"2015","unstructured":"Xue T, Le F, Chen R, Xie X, Zhang L, Ge N, et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Med Oncol. 2015;32(3):64.","journal-title":"Med Oncol"},{"issue":"13","key":"1947_CR8","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3748\/wjg.v21.i13.3970","volume":"21","author":"JH Li","year":"2015","unstructured":"Li JH, Xie XY, Zhang L, Le F, Ge NL, Li LX, et al. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3970\u20137.","journal-title":"World J Gastroenterol"},{"key":"1947_CR9","doi-asserted-by":"publisher","first-page":"2754542","DOI":"10.1155\/2016\/2754542","volume":"2016","author":"J Dong","year":"2016","unstructured":"Dong J, Zhai X, Chen Z, Liu Q, Ye H, Chen W, et al. Treatment of huge hepatocellular carcinoma using cinobufacini injection in transarterial chemoembolization: a retrospective study. Evid Based Complement Alternat Med. 2016;2016:2754542.","journal-title":"Evid Based Complement Alternat Med"},{"key":"1947_CR10","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.2147\/CMAR.S172395","volume":"10","author":"Y Wei","year":"2018","unstructured":"Wei Y, Dai F, Zhao T, Tao C, Wang L, Ye W, et al. Transcatheter arterial chemoembolization monotherapy vs combined transcatheter arterial chemoembolization-percutaneous microwave coagulation therapy for massive hepatocellular carcinoma (>\/=10 cm). Cancer Manag Res. 2018;10:5273\u201382.","journal-title":"Cancer Manag Res"},{"issue":"7","key":"1947_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/hepr.13335","volume":"49","author":"S Miyayama","year":"2019","unstructured":"Miyayama S, Kikuchi Y, Yoshida M, Yamashiro M, Sugimori N, Ikeda R, et al. Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma >\/=10 cm. Hepatol Res. 2019;49(7):787\u201398.","journal-title":"Hepatol Res"},{"issue":"8","key":"1947_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/life11080840","volume":"11","author":"GH Kim","year":"2021","unstructured":"Kim GH, Kim JH, Shim JH, Ko HK, Chu HH, Shin JH, et al. Chemoembolization for single large hepatocellular carcinoma with preserved liver function: analysis of factors predicting clinical outcomes in a 302 patient cohort. Life. 2021;11(8):840.","journal-title":"Life"},{"issue":"4","key":"1947_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/13645706.2020.1725580","volume":"30","author":"T Hidaka","year":"2021","unstructured":"Hidaka T, Anai H, Sakaguchi H, Sueyoshi S, Tanaka T, Yamamoto K, et al. Efficacy of combined bland embolization and chemoembolization for huge (>\/=10 cm) hepatocellular carcinoma. Minim Invasive Ther Allied Technol. 2021;30(4):221\u20138.","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"2","key":"1947_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00270-021-02777-6","volume":"45","author":"SCH Yu","year":"2022","unstructured":"Yu SCH, Hui JW, Li L, Cho CC, Hui EP, Chan SL, et al. Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (>\/= 10 cm) in Tumour Response and Long-Term Survival Outcome. Cardiovasc Intervent Radiol. 2022;45(2):172\u201381.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1947_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110223","volume":"194","author":"F Liu","year":"2024","unstructured":"Liu F, Brown DR, Munley MT. Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma. Radiother Oncol. 2024;194:110223.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1947_CR16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ijrobp.2022.09.077","volume":"115","author":"L Wei","year":"2023","unstructured":"Wei L, Simeth J, Aryal MP, Matuszak M, Haken RKT, Cuneo K, et al. The effect of stereotactic body radiation therapy for hepatocellular cancer on regional hepatic liver function. Int J Radiat Oncol Biol Phys. 2023;115(3):794\u2013802.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1947_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01605-4","volume":"15","author":"JY Cheng","year":"2020","unstructured":"Cheng JY, Liu CM, Wang YM, Hsu HC, Huang EY, Huang TT, et al. Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis. Radiat Oncol. 2020;15(1):159.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1947_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijrobp.2019.01.076","volume":"105","author":"NN Sanford","year":"2019","unstructured":"Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. Int J Radiat Oncol Biol Phys. 2019;105(1):64\u201372.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1947_CR19","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ijrobp.2009.02.030","volume":"76","author":"S Sugahara","year":"2010","unstructured":"Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010;76(2):460\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1947_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100675","volume":"6","author":"RS Bhangoo","year":"2021","unstructured":"Bhangoo RS, Mullikin TC, Ashman JB, Cheng TW, Golafshar MA, DeWees TA, et al. Intensity Modulated Proton Therapy for Hepatocellular Carcinoma: Initial Clinical Experience. Adv Radiat Oncol. 2021;6(4):100675.","journal-title":"Adv Radiat Oncol"},{"key":"1947_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.radonc.2020.02.019","volume":"146","author":"GS Yoo","year":"2020","unstructured":"Yoo GS, Yu JI, Cho S, Jung SH, Han Y, Park S, et al. Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. Radiother Oncol. 2020;146:187\u201393.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1947_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ijrobp.2008.10.073","volume":"74","author":"N Fukumitsu","year":"2009","unstructured":"Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74(3):831\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1947_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ijrobp.2010.07.015","volume":"81","author":"M Mizumoto","year":"2011","unstructured":"Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, et al. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys. 2011;81(4):1039\u201345.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1947_CR24","first-page":"1184","volume":"17","author":"G Wang","year":"2019","unstructured":"Wang G, Zhu S, Li X. Comparison of values of CT and MRI imaging in the diagnosis of hepatocellular carcinoma and analysis of prognostic factors. Oncol Lett. 2019;17(1):1184\u20138.","journal-title":"Oncol Lett"},{"issue":"4","key":"1947_CR25","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.ijrobp.2014.03.020","volume":"89","author":"JI Yu","year":"2014","unstructured":"Yu JI, Park HC, Lim DH, Choi Y, Jung SH, Paik SW, et al. The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89(4):814\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1947_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"1947_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000517393","volume":"10","author":"YW Hung","year":"2021","unstructured":"Hung YW, Lee IC, Chi CT, Lee RC, Liu CA, Chiu NC, et al. Redefining tumor burden in patients with intermediate-stage hepatocellular carcinoma: the seven-eleven criteria. Liver Cancer. 2021;10(6):629\u201340.","journal-title":"Liver Cancer"},{"issue":"7","key":"1947_CR28","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/archsurg.2010.118","volume":"145","author":"CM Schmidt","year":"2010","unstructured":"Schmidt CM, Turrini O, Parikh P, House MG, Zyromski NJ, Nakeeb A, et al. Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience. Arch Surg. 2010;145(7):634\u201340.","journal-title":"Arch Surg"},{"issue":"10","key":"1947_CR29","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1002\/cam4.1756","volume":"7","author":"AO Naghavi","year":"2018","unstructured":"Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Venkat PS, Ahmed KA, et al. Patient choice for high-volume center radiation impacts head and neck cancer outcome. Cancer Med. 2018;7(10):4964\u201379.","journal-title":"Cancer Med"},{"issue":"1","key":"1947_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijrobp.2018.05.038","volume":"102","author":"SM Lin","year":"2018","unstructured":"Lin SM, Ku HY, Chang TC, Liu TW, Chang CS, Hong JH. Outcomes for cervical cancer patients treated with radiation in high-volume and low-volume hospitals. Int J Radiat Oncol Biol Phys. 2018;102(1):184\u201393.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1947_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020357","volume":"16","author":"H Niitsu","year":"2024","unstructured":"Niitsu H, Mizumoto M, Li Y, Nakamura M, Ishida T, Iizumi T, et al. Tumor response on diagnostic imaging after proton beam therapy for hepatocellular carcinoma. Cancers. 2024;16(2):357.","journal-title":"Cancers"},{"key":"1947_CR32","doi-asserted-by":"crossref","unstructured":"Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, et al. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver. 2020;14(6):765\u201374.","DOI":"10.5009\/gnl19197"},{"issue":"7","key":"1947_CR33","doi-asserted-by":"publisher","first-page":"e922","DOI":"10.1093\/oncolo\/oyae048","volume":"29","author":"CW Su","year":"2024","unstructured":"Su CW, Teng W, Shen EY, Huang BS, Lin PT, Hou MM, et al. Concurrent Atezolizumab plus Bevacizumab and high-dose external beam radiotherapy for highly advanced hepatocellular carcinoma. Oncologist. 2024;29(7):e922\u201331.","journal-title":"Oncologist"},{"issue":"3","key":"1947_CR34","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/j.ijrobp.2011.05.056","volume":"82","author":"M Mizumoto","year":"2012","unstructured":"Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, et al. Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(3):e529\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1947_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203854","volume":"13","author":"CH Lee","year":"2018","unstructured":"Lee CH, Hung SP, Hong JH, Chang JT, Tsang NM, Chan KM, et al. How small is TOO small? New liver constraint is needed- Proton therapy of hepatocellular carcinoma patients with small normal liver. PLoS ONE. 2018;13(9):e0203854.","journal-title":"PLoS ONE"},{"issue":"10474","key":"1947_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405(10474):216\u201332.","journal-title":"Lancet"},{"issue":"3","key":"1947_CR37","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.21873\/anticanres.16284","volume":"43","author":"JY Cheng","year":"2023","unstructured":"Cheng JY, Huang BS, Chen YY, Wang CC, Chen YH. Combination of Lenvatinib and proton beam therapy in the management of patients with advanced hepatocellular carcinoma. Anticancer Res. 2023;43(3):1361\u201371.","journal-title":"Anticancer Res"},{"key":"1947_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2020.07.046","volume":"152","author":"WH Lee","year":"2020","unstructured":"Lee WH, Byun HK, Choi JS, Choi GH, Han DH, Joo DJ, et al. Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria. Radiother Oncol. 2020;152:1\u20137.","journal-title":"Radiother Oncol"},{"issue":"4","key":"1947_CR39","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.ijrobp.2024.01.221","volume":"119","author":"J Kim","year":"2024","unstructured":"Kim J, Kim YT, Lee JG, Han DH, Joo DJ, Kim DY, et al. Liver-directed combined radiation therapy for downstaging beyond-Milan hepatocellular carcinoma to liver transplantation. Int J Radiat Oncol Biol Phys. 2024;119(4):1171\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1947_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):169\u201378.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1947_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.21037\/hbsn-21-379","volume":"11","author":"CL Chen","year":"2022","unstructured":"Chen CL, Ong AD, Cheng JY, Yong CC, Lin CC, Chen CY, et al. Proton beam therapy to bridge or downstage locally advanced hepatocellular carcinoma to living donor liver transplantation. Hepatobiliary Surg Nutr. 2022;11(1):103\u201311.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"6","key":"1947_CR42","doi-asserted-by":"publisher","first-page":"966","DOI":"10.21037\/hbsn-23-410","volume":"12","author":"CL Chen","year":"2023","unstructured":"Chen CL, Dungca LBP, Yong CC, Chen IC, Cheng YF, Cheng JY, et al. Proton beam therapy for downstaging hepatocellular carcinoma with lobar portal vein tumor thrombosis to living donor liver transplantation. Hepatobiliary Surg Nutr. 2023;12(6):966\u201374.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"5","key":"1947_CR43","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.1840210515","volume":"21","author":"K Urata","year":"1995","unstructured":"Urata K, Kawasaki S, Matsunami H, Hashikura Y, Ikegami T, Ishizone S, et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 1995;21(5):1317\u201321.","journal-title":"Hepatology"},{"issue":"3","key":"1947_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijrobp.2023.09.047","volume":"118","author":"M Mizumoto","year":"2024","unstructured":"Mizumoto M, Ogino H, Okumura T, Terashima K, Murakami M, Ogino T, et al. Proton beam therapy for hepatocellular carcinoma: multicenter prospective registry study in Japan. Int J Radiat Oncol Biol Phys. 2024;118(3):725\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1947_CR45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0360-3016(02)02864-X","volume":"54","author":"HC Park","year":"2002","unstructured":"Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2002;54(1):150\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01947-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-01947-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01947-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:03:05Z","timestamp":1780120985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-01947-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-01947-1","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the institutional review board (IRB) of the Chang Gung Medical Foundation (reference number 202400637B0).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}